## Uwe Pleyer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5061958/publications.pdf

Version: 2024-02-01

		136950	168389
101	3,469	32	53
papers	citations	h-index	g-index
132	132	132	3041
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Effect of Anti-TNF Treatment on Mooren's Ulcer: A Case Series and Review of the Literature. Ocular Immunology and Inflammation, 2022, , 1-7.	1.8	2
2	Cytomegalovirus-Positive Posner-Schlossman Syndrome: Impact on Corneal Endothelial Cell Loss and Retinal Nerve Fiber Layer Thinning. American Journal of Ophthalmology, 2022, 237, 290-298.	3.3	9
3	Virale anteriore Uveitis. Klinische Monatsblatter Fur Augenheilkunde, 2022, , .	0.5	1
4	Findings and Graduation of Sarcoidosis-Related Uveitis: A Single-Center Study. Cells, 2022, 11, 89.	4.1	5
5	A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments. Journal of Clinical Medicine, 2022, 11, 2525.	2.4	11
6	<scp>Anti D20</scp> therapy for multiple sclerosisâ€associated uveitis: AÂcase series. European Journal of Neurology, 2022, 29, 3028-3038.	3.3	3
7	New pharmacotherapy options for noninfectious posterior uveitis. International Ophthalmology, 2021, 41, 2265-2281.	1.4	14
8	Screening for common eye diseases in the elderly with Optos ultra-wide-field scanning laser ophthalmoscopy: a pilot study with focus on ocular toxoplasmosis. International Ophthalmology, 2021, 41, 1573-1584.	1.4	3
9	Treatment Strategy in Human Ocular Toxoplasmosis: Why Antibiotics Have Failed. Journal of Clinical Medicine, 2021, 10, 1090.	2.4	12
10	Acute macular neuroretinopathy (AMN) following COVID-19 vaccination. American Journal of Ophthalmology Case Reports, 2021, 24, 101207.	0.7	20
11	HLA-B27 assoziierte anteriore Uveitis: Herausforderung für eine interdisziplinÃÆ Zusammenarbeit. Aktuelle Rheumatologie, 2021, 46, 524-531.	0.1	O
12	Hintergrund/diagnostische Grundkonzepte. , 2021, , 325-377.		0
13	Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2095173.	2.7	32
14	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097261.	2.7	17
15	Optical coherence tomography angiography (OCTA) findings in Serpiginous Choroiditis. BMC Ophthalmology, 2020, 20, 258.	1.4	5
16	Omalizumab in three children with severe vernal keratoconjunctivitis. Allergo Journal International, 2020, 29, 181-186.	2.0	4
17	Virus-associated anterior uveitis and secondary glaucoma: Diagnostics, clinical characteristics, and surgical options. PLoS ONE, 2020, 15, e0229260.	2.5	14
18	Sympathetic Ophthalmia – a Contribution to Immunology, Clinic and Current Imaging. Klinische Monatsblatter Fur Augenheilkunde, 2020, 237, 1060-1069.	0.5	6

#	Article	IF	Citations
19	Dexamethasone Intraocular Suspension: A Long-Acting Therapeutic for Treating Inflammation Associated with Cataract Surgery. Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 525-534.	1.4	9
20	Emerging drugs for the treatment of noninfectious uveitis. Expert Opinion on Emerging Drugs, 2019, 24, 173-190.	2.4	11
21	Re: Hughes etÂal.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis (Ophthalmology. 2019;126:415-424). Ophthalmology, 2019, 126, e75-e76.	5.2	0
22	<p>Systemic exposure to intracameral vs topical mydriatic agents: in cataract surgery</p> . Clinical Ophthalmology, 2019, Volume 13, 811-819.	1.8	9
23	Immune Mediator Profile in Aqueous Humor Differs in Patients with Primary Acquired Ocular Toxoplasmosis and Recurrent Acute Ocular Toxoplasmosis. Mediators of Inflammation, 2019, 2019, 1-12.	3.0	18
24	High-risk Corneal Transplantation: Recent Developments and Future Possibilities. Transplantation, 2019, 103, 2468-2478.	1.0	75
25	Immunosuppressants and/or antivascular endothelial growth factor inhibitors in punctate inner choroidopathy? Follow-up results with optical coherence tomography angiography. British Journal of Ophthalmology, 2019, 103, 1152-1157.	3.9	13
26	Optical coherence tomography angiography in comparison with other multimodal imaging techniques in punctate inner choroidopathy. British Journal of Ophthalmology, 2019, 103, 60-66.	3.9	32
27	Toxoplasmosis in Germany: Epidemiology, Diagnosis, Risk Factors, and Treatment. Deutsches Ärzteblatt International, 2019, 116, 435-444.	0.9	36
28	Dexamethasone Inserts in Noninfectious Uveitis. Ophthalmology, 2018, 125, 1088-1099.	5.2	43
29	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology, 2018, 125, 757-773.	5.2	178
30	Pupil dilation dynamics with an intracameral fixed combination of mydriatics and anesthetic during cataract surgery. Journal of Cataract and Refractive Surgery, 2018, 44, 341-347.	1.5	19
31	Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clinical Ophthalmology, 2018, Volume 12, 2519-2534.	1.8	21
32	Vascular Endothelial Growth Factor (VEGF) Induced Downstream Responses to Transient Receptor Potential Vanilloid 1 (TRPV1) and 3-lodothyronamine (3-T1AM) in Human Corneal Keratocytes. Frontiers in Endocrinology, 2018, 9, 670.	3.5	16
33	Different composition of intraocular immune mediators in Posner-Schlossman-Syndrome and Fuchs' Uveitis. PLoS ONE, 2018, 13, e0199301.	2.5	30
34	Challenges with cataract surgery in pars planitis patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1483-1484.	1.9	4
35	Small molecules as therapy for uveitis: a selected perspective of new and developing agents. Expert Opinion on Pharmacotherapy, 2017, 18, 1311-1323.	1.8	16
36	Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmology, 2017, 17, 252.	1.4	13

#	Article	IF	CITATIONS
37	Upregulation of Transient Receptor Potential Vanilloid Type-1 Channel Activity and Ca2+Influx Dysfunction in Human Pterygial Cells., 2016, 57, 2564.		21
38	Sirolimus for the treatment of noninfectious uveitis. Expert Opinion on Pharmacotherapy, 2016, 17, 127-135.	1.8	12
39	Surgical, antiseptic, and antibiotic practice in cataract surgery: Results from the European Observatory in 2013. Journal of Cataract and Refractive Surgery, 2015, 41, 2635-2643.	1.5	27
40	Current aspects on the management of viral uveitis in immunocompetent individuals. Clinical Ophthalmology, 2015, 9, 1017.	1.8	61
41	Subretinal Fluid in Eyes with Active Ocular Toxoplasmosis Observed Using Spectral Domain Optical Coherence Tomography. PLoS ONE, 2015, 10, e0127683.	2.5	8
42	Uveitis in Juvenile Idiopathic Arthritis. Deutsches A& #x0308; rzteblatt International, 2015, 112, 92-100, i.	0.9	48
43	Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy. Ophthalmology, 2015, 122, 939-948.	5.2	139
44	Controversies in NSAIDs Use in Cataract Surgery. Current Pharmaceutical Design, 2015, 21, 4707-4717.	1.9	9
45	Evaluation of Cystoid Change Phenotypes in Ocular Toxoplasmosis Using Optical Coherence Tomography. PLoS ONE, 2014, 9, e86626.	2.5	24
46	Fast and Successful Management of Intraocular Inflammation with a Single Intravitreal Dexamethasone Implant. Ophthalmologica, 2014, 232, 223-229.	1.9	24
47	Genotyping of samples from German patients with ocular, cerebral and systemic toxoplasmosis reveals a predominance of Toxoplasma gondii type II. International Journal of Medical Microbiology, 2014, 304, 911-916.	3.6	44
48	New pharmacotherapy options for noninfectious posterior uveitis. Expert Opinion on Biological Therapy, 2014, 14, 1783-1799.	3.1	15
49	OkulÃÆ OberflÃæhe – nicht infektiös. , 2014, , 117-180.		0
50	Prevention and Treatment of Transplant Rejection in Keratoplasty. , 2014, , 95-116.		0
51	Functional significance of thermosensitive transient receptor potential melastatin channel 8 (TRPM8) expression in immortalized human corneal endothelial cells. Experimental Eye Research, 2013, 116, 337-349.	2.6	29
52	Intraocular Pressure Effects of Common Topical Steroids for Post-Cataract Inflammation: Are They All the Same?. Ophthalmology and Therapy, 2013, 2, 55-72.	2.3	99
53	Think Global – Act Local: Intravitreal Drug Delivery Systems in Chronic Noninfectious Uveitis. Ophthalmic Research, 2013, 49, 59-65.	1.9	29
54	Calcium regulation by thermo- and osmosensing transient receptor potential vanilloid channels (TRPVs) in human conjunctival epithelial cells. Histochemistry and Cell Biology, 2012, 137, 743-761.	1.7	43

#	Article	IF	Citations
55	Characterization of transient receptor potential vanilloid channel 4 (TRPV4) in human corneal endothelial cells. Experimental Eye Research, 2011, 93, 710-719.	2.6	39
56	Understanding uveitis: The impact of research on visual outcomes. Progress in Retinal and Eye Research, 2011, 30, 452-470.	15.5	272
57	Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2010) Anti-TNF Agents for Behçet´s disease: analysis of published data on 369 patients. Semin Arthritis Rheum [PMID:21168186]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 1273-1275.	1.9	1
58	Thermosensitive transient receptor potential channels in human corneal epithelial cells. Journal of Cellular Physiology, 2011, 226, 1828-1842.	4.1	51
59	Control of TNF-Induced Dendritic Cell Maturation by Hybrid-Type <i>N</i> -Glycans. Journal of Immunology, 2011, 186, 5201-5211.	0.8	6
60	Intraocular antibody synthesis against rubella virus and other microorganisms in Fuchs' heterochromic cyclitis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 565-571.	1.9	79
61	Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248, 1447-1456.	1.9	28
62	TRPV channels mediate temperature-sensing in human corneal endothelial cells. Experimental Eye Research, 2010, 90, 758-770.	2.6	61
63	Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment. Current Eye Research, 2010, 35, 751-756.	1.5	82
64	Novel gene therapeutic strategies for the induction of tolerance in cornea transplantation. Expert Review of Clinical Immunology, 2009, 5, 749-764.	3.0	12
65	The taming of the shrew? The immunology of corneal transplantation. Acta Ophthalmologica, 2009, 87, 488-497.	1.1	40
66	Corneal allograft endothelial cell replacement represents a reparative response to transplant injury. Molecular Vision, 2009, 15, 654-61.	1.1	2
67	Dependence of regulatory volume decrease on transient receptor potential vanilloid 4 (TRPV4) expression in human corneal epithelial cells. Cell Calcium, 2008, 44, 374-385.	2.4	76
68	Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. Journal of Rheumatology, 2008, 35, 896-903.	2.0	71
69	Local Overexpression of Nerve Growth Factor in Rat Corneal Transplants Improves Allograft Survival., 2007, 48, 1043.		45
70	Effects of interleukin-12p40 gene transfer on rat corneal allograft survival. Transplant Immunology, 2007, 18, 101-107.	1.2	26
71	Transient receptor potential vanilloid $1$ activation induces inflammatory cytokine release in corneal epithelium through MAPK signaling. Journal of Cellular Physiology, 2007, 213, 730-739.	4.1	118
72	The influence of inducible costimulator fusion protein (ICOSIg) gene transfer on corneal allograft survival. Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245, 1515-1521.	1.9	14

#	Article	IF	Citations
73	Specific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 210-215.	1.9	24
74	Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. Journal of Gene Medicine, 2006, 8, 459-467.	2.8	47
75	Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty. Graefe's Archive for Clinical and Experimental Ophthalmology, 2005, 243, 450-455.	1.9	8
76	TRPC4 Knockdown Suppresses Epidermal Growth Factor-induced Store-operated Channel Activation and Growth in Human Corneal Epithelial Cells. Journal of Biological Chemistry, 2005, 280, 32230-32237.	3.4	77
77	Lipid-mediated gene transfer of acidic fibroblast growth factor into human corneal endothelial cells. Experimental Eye Research, 2005, 80, 93-101.	2.6	28
78	Immunomodulatory Therapy in Ophthalmology – Is There a Place for Topical Application?. Ophthalmologica, 2004, 218, 359-367.	1.9	50
79	Gene therapy in immune-mediated diseases of the eye. Progress in Retinal and Eye Research, 2003, 22, 277-293.	15.5	16
80	Intraocular Availability of Topically Applied Mycophenolate Mofetil in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2003, 19, 181-192.	1.4	22
81	Efficiency of Cytokine Gene Transfer in Corneal Endothelial Cells and Organ-Cultured Corneas Mediated by Liposomal Vehicles and Recombinant Adenovirus. Ophthalmic Research, 2003, 35, 117-124.	1.9	32
82	Outcome of Penetrating Keratoplasty in Rheumatoid Arthritis. Ophthalmologica, 2002, 216, 249-255.	1.9	37
83	Corticosteroids in Ophthalmology: Past – Present – Future. Ophthalmologica, 2002, 216, 305-315.	1.9	60
84	Corneal Allograft Rejection: Current Understanding. Ophthalmologica, 2002, 216, 2-12.	1.9	27
85	Delivery of genes via liposomes to corneal endothelial cells. Drug News and Perspectives, 2002, 15, 283.	1.5	14
86	Efficiency and Toxicity of Liposome-mediated Gene Transfer to Corneal Endothelial Cells. Experimental Eye Research, 2001, 73, 1-7.	2.6	43
87	Corneal Allograft Rejection: Current Understanding. Ophthalmologica, 2001, 215, 254-262.	1.9	23
88	Immune tolerance and gene therapy in transplantation. Trends in Immunology, 2000, 21, 12-14.	<b>7.</b> 5	14
89	The Role of Endogenous Growth Factors to Support Corneal Endothelial Migration after Wounding in vitro. Experimental Eye Research, 2000, 71, 583-589.	2.6	36
90	Delayed mustard gas keratopathy: clinical findings and confocal microscopy. American Journal of Ophthalmology, 1999, 128, 506-507.	3.3	66

#	Article	IF	CITATION
91	Adenovirus-Mediated Gene Transfer of Interleukin-4 to Corneal Endothelial Cells and Organ Cultured Corneas Leads to High IL-4 Expression. Experimental Eye Research, 1999, 69, 563-568.	2.6	36
92	Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocular Immunology and Inflammation, 1998, 6, 51-56.	1.8	29
93	Determinations of serum tumor necrosis factor alpha in corneal allografts. Ocular Immunology and Inflammation, 1997, 5, 149-155.	1.8	24
94	Traumatic wound dehiscence after penetrating keratoplasty. Acta Ophthalmologica, 1996, 74, 501-505.	0.3	31
95	Analysis of interactions between the corneal epithelium and liposomes: Qualitative and quantitative fluorescence studies of a corneal epithelial cell line. Survey of Ophthalmology, 1995, 39, S3-S16.	4.0	18
96	Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. Current Eye Research, 1994, 13, 177-181.	1.5	52
97	Prolongation of Corneal Allograft Survival with Liposome-encapsulated Cyclosporine in the Rat Eye. Ophthalmology, 1993, 100, 890-896.	5.2	71
98	Collagen Shields Impregnated With Gentamicin-dexamethasone as a Potential Drug Delivery Device. American Journal of Ophthalmology, 1993, 116, 622-627.	3.3	34
99	Device Drug Delivery to the Eye. Ophthalmology, 1991, 98, 725-732.	5.2	80
100	Peripheral blood immune cell profiling of acute corneal transplant rejection. American Journal of Transplantation, 0, , .	4.7	1
101	Rubella Virus- and Cytomegalovirus-Associated Anterior Uveitis: Clinical Findings and How They Relate to the Current Fuchs Uveitis Syndrome Classification. Frontiers in Ophthalmology, 0, 2, .	0.5	2